FIGURE 2.

Mutation status and mutation number of MUC4, MUC16, and TTN predict TMB, prognosis, and immunotherapy efficacy in SYSUCC and pan‐cancer cohort. A and B, MUC4, MUC16, and TTN mutations had higher TMB in SYSUCC and pan‐cancer cohort. C and D, ROC curve using gene mutation numbers to estimate TMB status. E, High mutation numbers of MUC4, MUC16, and TTN genes showed better OS, PFS, and immunotherapy efficacy in SYSUCC cohort. F‐H, TMB status, mutation numbers of MUC4 plus TTN, and mutation numbers of MUC4, MUC16 plus TTN were correlated with OS, PFS, and ORR in pan‐cancer cohort